Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency
Park J, Riaz M, Qin L, Zhang W, Batty L, Fooladi S, Kural M, Li X, Luo H, Xu Z, Wang J, Banno K, Gu S, Yuan Y, Anderson C, Ellis M, Zhou J, Luo J, Shi X, Shin J, Liu Y, Lee S, Yoder M, Elder R, Mak M, Thorn S, Sinusas A, Gruber P, Hwa J, Tellides G, Niklason L, Qyang Y. Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency. Cell Stem Cell 2024 PMID: 39644899, DOI: 10.1016/j.stem.2024.11.006.Peer-Reviewed Original ResearchTissue-engineered vascular conduitsSingle-ventricle congenital heart defectsEndothelial cellsBiodegradable polymeric scaffoldsGraft patencyAutologous bone marrow cellsAntithrombotic functionCongenital heart defectsInferior vena cava graftHiPSC-derived endothelial cellsBone marrow cellsHuman umbilical arteryDecellularized human umbilical arteriesPolymeric scaffoldsHost endothelial cellsHuman induced pluripotent stem cell (hiPSC)-derived endothelial cellsUmbilical arteryHeart defectsVascular conduitsMarrow cellsFlow bioreactorVena cava graftNude ratsGraft stenosisClinical trials